Who is sponsoring NCT04358809?

NCT04358809 is sponsored by Cadila Pharnmaceuticals.

What drugs are being tested in NCT04358809?

Interventions in NCT04358809: Suspension of heat killed (autoclaved) Mycobacterium w, Placebo.

Is NCT04358809 still recruiting?

NCT04358809 is currently status unknown. Last updated 22 December 2020.

Last reviewed 2020-12-22 · How we verify

NCT04358809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill

Status unknown Phase 3 Last updated 22 December 2020

What this trial tests

Phase 3 trial testing Suspension of heat killed (autoclaved) Mycobacterium w in COVID-19 in 480 participants. Status unknown.

Timeline

30 June 2020

Primary endpoint
28 February 2021

30 April 2021

Quick facts

Lead sponsor	Cadila Pharnmaceuticals
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	480
Start date	30 June 2020
Primary completion	28 February 2021
Estimated completion	30 April 2021
Sites	4 locations across India

Drugs / interventions tested

Suspension of heat killed (autoclaved) Mycobacterium w — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Cadila Pharnmaceuticals — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.
Hossain MS, Hami I, Sawrav MSS, Rabbi MF, et al · · 2020 · cited 16× · PMID 33403227 · DOI 10.15190/d.2020.18
Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review.
Mathioudakis AG, Fally M, Hashad R, Kouta A, et al · · 2020 · cited 14× · PMID 33333777 · DOI 10.3390/life10120350
Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19.
Jaiswal SR, Arunachalam J, Saifullah A, Lakhchaura R, et al · · 2022 · cited 9× · PMID 35603154 · DOI 10.3389/fimmu.2022.887230
Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?
Ehtesham NZ, Samal J, Ahmad F, Arish M, et al · · 2020 · cited 7× · PMID 32859863 · DOI 10.4103/ijmr.ijmr_1563_20

Verify or expand the search:

Other trials of Suspension of heat killed (autoclaved) Mycobacterium w

Trials testing the same drug.

NCT04353518 — Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 · Phase 3 · unknown
NCT04347174 — A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Cadila Pharnmaceuticals trials

Trials by the same sponsor.

NCT04353518 — Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 · Phase 3 · unknown
NCT04347174 — A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients · NA · completed
NCT04801199 — Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus · Phase 3 · completed
NCT05174598 — A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With · Phase 3 · completed
NCT00694915 — Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04358809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cadila Pharnmaceuticals
Last refreshed: 22 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04358809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing